Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Leading Cancer Researcher Appointed NIMHD Clinical Director

Published: Friday, January 25, 2013
Last Updated: Thursday, January 24, 2013
Bookmark and Share
Dr. Reed will oversee outpatient, inpatient, epidemiological, clinical, and laboratory based studies.

The National Institute on Minority Health and Health Disparities (NIMHD) of the National Institutes of Health has announced that Eddie Reed, M.D., an award-winning physician and internationally recognized cancer researcher, will serve as the clinical director for the NIMHD Intramural Research Program.

“Dr. Reed is a world renowned oncologist with extensive experience managing clinical trials and translating science into health,” said NIMHD Director John Ruffin, Ph.D.

Ruffin continued, “The breadth of his knowledge of health disparities and public health and the depth of his experience in cancer pharmacology will serve us well as we build the clinical research program within the NIMHD Intramural Research Program.”

Prior to joining NIMHD, Dr. Reed most recently served as professor of oncologic sciences and Abraham Mitchell Distinguished Investigator at the University of South Alabama’s Mitchell Cancer Institute, Mobile, where he has worked closely with the state of Alabama on life-saving cancer screening and control programs.

Dr. Reed has previously served as a tenured scientist, chief of the Clinical Pharmacology Branch, and chief of the Ovarian Cancer and Metastatic Prostate Cancer Clinic in the Division of Clinical Science at the National Cancer Institute (NCI); director of the Mary Babb Randolph Cancer Center at West Virginia University, Morgantown; and director of the Division of Cancer Prevention and Control at the Centers for Disease Control and Prevention.

Dr. Reed’s clinical research has primarily been focused on DNA damage and repair in cancer cells in response to pharmacological anticancer agents.

He has conducted more than four dozen phase I or phase II clinical trials of these agents and received two United States Public Health Service Commendation Medals for his work on the clinical development of the powerful anti-cancer agent, paclitaxel.

Paclitaxel is used to treat a variety of cancers including lung, breast, ovarian, and head and neck cancers. He has also collaborated on many public health cancer prevention, screening, and control programs throughout his career many of which were focused on reducing health disparities.

Dr. Reed received his undergraduate degree from Philander Smith College in Little Rock, Ark., and his medical degree from Yale University School of Medicine in New Haven, Conn. He completed his internship and residency at Stanford University in Palo Alto, Calif., and a fellowship at NCI in Bethesda, Md.

He is board certified in internal medicine and has been listed as a Top Doctor by the US News and World Report. He served on the Institute of Medicine’s National Cancer Policy Forum from 2005-2008. He has also served on the National Advisory Council on Minority Health and Health Disparities.

As clinical director, Dr. Reed will oversee a combination of studies including outpatient, inpatient, epidemiological, clinical, and laboratory based studies.

He will build a multi- and inter-disciplinary research program geared to translating basic research into clinical trials and ultimately interventions.

He will lead the NIMHD effort in enhancing the recruitment and retention of minorities and other underserved populations in clinical trials.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cancer Drug Target Visualized at Atomic Resolution
New study using cryo-electron microscopy shows how potential drugs could inhibit cancer.
Thursday, February 04, 2016
Scientists Develop Genetic Blueprint of Inner Ear Cell Development
Two studies in mice use new technique to provide insight into cell development critical for hearing, balance.
Saturday, October 17, 2015
NIH Breast Cancer Research to Focus On Prevention
A new phase of the Breast Cancer and the Environment Research Program (BCERP), focused on prevention, is being launched at the National Institutes of Health.
Friday, October 09, 2015
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Tuesday, October 06, 2015
Cellular Factors that Shape the 3D Landscape of the Genome Identified
Researchers have identified 50 cellular factors required for the proper 3D positioning of genes by using novel large-scale imaging technology.
Tuesday, August 18, 2015
Tell-tale Biomarker Detects Early Breast Cancer in NIH-funded Study
The study published online in the issue of Nature Communications.
Thursday, August 13, 2015
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
Tuesday, July 21, 2015
Potential Therapeutic for Blinding Eye Disease
NIH research points to microglia as potential therapeutic target in retinitis pigmentosa.
Thursday, July 02, 2015
NCI-MATCH Trial will Link Targeted Cancer Drugs to Gene Abnormalities
Precision medicine trial will open to patient enrollment in July.
Tuesday, June 09, 2015
Linking Targeted Cancer Drugs to Gene Abnormalities
Investigators at the NIH have announced a series of clinical trials that will study drugs or drug combinations that target specific genetic mutations.
Wednesday, June 03, 2015
Lipid Nanoparticle Therapeutic Treats Ebola in Monkeys
A newly designed agent was effective in treating monkeys infected with a deadly Ebola virus strain.
Wednesday, May 06, 2015
Possible Treatment for Lethal Pediatric Brain Cancer
NIH-funded preclinical study suggests epigenetic drugs may be used to treat leading cause of pediatric brain cancer death.
Tuesday, May 05, 2015
NIH Study Finds Genetic Link for Rare Intestinal Cancer
Researchers recommend screening for people with family history.
Friday, April 17, 2015
Novel Approach Gives Insights Into Tumor Development
Scientists used a powerful new technique to turn off all the genes in mouse lung cancer cells and test how they affect tumor growth and metastasis.
Tuesday, March 24, 2015
Strengthening the Immune System’s Fight Against Brain Cancer
NIH-funded research suggests novel way to improve vaccine efficacy in brain tumors.
Friday, March 20, 2015
Scientific News
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Cancer Drug Target Visualized at Atomic Resolution
New study using cryo-electron microscopy shows how potential drugs could inhibit cancer.
Genetic Mechanism Behind Cancer-Causing Mutations
Researchers at Indiana University has identified a genetic mechanism that is likely to drive mutations that can lead to cancer.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
Enzyme Links Age-Related Inflammation, Cancer
Researchers have shown that an enzyme key to regulating gene expression -- and also an oncogene when mutated -- is critical for the expression of numerous inflammatory compounds that have been implicated in age-related increases in cancer and tissue degeneration.
Viral Gene Editing System Corrects Genetic Liver Disease
Penn study has implications for developing safe therapies for an array of rare diseases via new gene cut-and-paste methods.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Curing Disease by Repairing Faulty Genes
New delivery method boosts efficiency of CRISPR genome-editing system.
'Junk' DNA Plays Role in Preventing Breast Cancer
Supposed "junk" DNA, found in between genes, plays a role in suppressing cancer, according to new research by Universities of Bath and Cambridge.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!